Equities
  • Price (USD)16.18
  • Today's Change3.30 / 25.62%
  • Shares traded3.67k
  • 1 Year change+211.15%
  • Beta0.0406
Data delayed at least 15 minutes, as of Feb 10 2026 19:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sumitomo Pharma Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through three geographical segments. The Japan segment is engaged in the manufacture, purchase, and sale of prescription drugs, purchase and sale of medical devices, undertakes development and manufacture in the field of regenerative medicine and cellular medicine, and the manufacture of pharmaceuticals, medical devices, and regenerative medicine products that have been developed through joint development in the field of regenerative medicine. This segment also provides storage and delivery service of pharmaceuticals. The North America segment is engaged in the manufacture, purchase, and sale of prescription drugs. The Asia segment is engaged in the manufacture and sale of prescription drugs (small packaging), and the import, purchase and sale of prescription drugs in Southeast Asia and Taiwan, as well as the provision and collection of information on products.

  • Revenue in JPY (TTM)453.40bn
  • Net income in JPY110.09bn
  • Incorporated1897
  • Employees3.83k
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.